20% of 2019-nCoV Patients May Progress to Severe Disease
WHO and China reiterated mutual commitment to bring the 2019-nCoV outbreak under control
A World Health Organization (WHO) senior leadership team, led by Director-General Dr. Tedros Adhanom Ghebreyesus, met President Xi Jinping of the People’s Republic of China in Beijing.
They shared the latest information on the outbreak as of January 28, 2020, and reiterated their mutual commitment to bring the 2019-nCoV outbreak under control.
The discussions focused on continued collaboration to improve containment measures in Wuhan, China, to strengthen public health measures in other cities and provinces, to conduct further studies and transmissibility of the virus, to continue to share data, and for China to share biological material with WHO.
These measures will advance scientific understanding of the virus and contribute to the development of vaccines and treatments.
Patients with 2019-nCoV infection are presenting with a wide range of symptoms. Most seem to have mild disease, and about 20 percent appear to progress to severe disease, including pneumonia, respiratory failure, and in some cases death.
Clinical care of suspected patients with 2019-nCoV infections should focus on early recognition, immediate isolation (separation), implementation of appropriate infection prevention and control (IPC) measures, and provision of optimized supportive care.
Additionally, the WHO announced it is launching a Global 2019-nCoV Clinical Data Platform to enable WHO Member States to contribute anonymized clinical data in order to inform the public health clinical response.
Furthermore, the WHO is continually monitoring the outbreak developments and the Director-General can reconvene the Emergency Committee on very short notice as needed.
As of January 29, 2020, the US Food and Drug Administration (FDA) has not approved any preventive or therapeutic vaccine for the 2019-nCoV for use in the USA.
In response to the current 2019-nCoV virus outbreak, Dr. Anthony S. Fauci, director of the NIAID said during an HHS press conference on January 28, 2020, "A phase 1 clinical trial does not mean you have a (coronavirus) vaccine that’s ready for deployment. It could take a year or more before a vaccine is ready for sale to the public."
Coronaviruses (CoV) are a large family of viruses that cause illness ranging from the common cold to more severe diseases, says the US Centers for Disease Control and Prevention (CDC).
Coronaviruses that infect animals can also evolve and become a human coronavirus.
The best-known human coronaviruses are Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV).
Outbreaks of a Novel Coronavirus (nCoV), now known as 2019-nCoV, are causing pneumonia-related infections in various counties in 2020.
The WHO said it is convening a bi-weekly call with clinical experts around the globe, to better understand, in real-time, the clinical presentation and treatment interventions.
International news related to the 2019-nCoV outbreak is published by Vax-Before-Travel.